Research
Aurélien de la Torre is awarded an ERC Consolidator grant
… in 2009 and which induced a paradigm shift in drug design. The first recommendation (higher proportion of Csp3) … offering a comparable biological action. In drug design, it is used to improve efficacy or reduce toxicity … in 2009 and which induced a paradigm shift in drug design. The first recommendation (higher proportion of Csp3) …Published on: